273 related articles for article (PubMed ID: 25855971)
1. A systematic review of studies eliciting willingness-to-pay per quality-adjusted life year: does it justify CE threshold?
Nimdet K; Chaiyakunapruk N; Vichansavakul K; Ngorsuraches S
PLoS One; 2015; 10(4):e0122760. PubMed ID: 25855971
[TBL] [Abstract][Full Text] [Related]
2. Estimating the range of incremental cost-effectiveness thresholds for healthcare based on willingness to pay and GDP per capita: A systematic review.
Iino H; Hashiguchi M; Hori S
PLoS One; 2022; 17(4):e0266934. PubMed ID: 35421181
[TBL] [Abstract][Full Text] [Related]
3. Willingness to pay per quality-adjusted life year for life-saving treatments in Thailand.
Nimdet K; Ngorsuraches S
BMJ Open; 2015 Oct; 5(10):e008123. PubMed ID: 26438135
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of willingness to pay per quality-adjusted life year for a cure: A contingent valuation method using a scenario-based survey.
Song HJ; Lee EK
Medicine (Baltimore); 2018 Sep; 97(38):e12453. PubMed ID: 30235732
[TBL] [Abstract][Full Text] [Related]
5. Willingness to pay for a QALY based on community member and patient preferences for temporary health states associated with herpes zoster.
Lieu TA; Ray GT; Ortega-Sanchez IR; Kleinman K; Rusinak D; Prosser LA
Pharmacoeconomics; 2009; 27(12):1005-16. PubMed ID: 19908925
[TBL] [Abstract][Full Text] [Related]
6. A systematic review on the direct approach to elicit the demand-side cost-effectiveness threshold: Implications for low- and middle-income countries.
Nu Vu A; Hoang MV; Lindholm L; Sahlen KG; Nguyen CTT; Sun S
PLoS One; 2024; 19(2):e0297450. PubMed ID: 38329955
[TBL] [Abstract][Full Text] [Related]
7. On what basis are medical cost-effectiveness thresholds set? Clashing opinions and an absence of data: a systematic review.
Cameron D; Ubels J; Norström F
Glob Health Action; 2018; 11(1):1447828. PubMed ID: 29564962
[TBL] [Abstract][Full Text] [Related]
8. A Contingent Valuation Study for Eliciting a Monetary Value of a Quality-Adjusted Life-Year in the General Greek Population.
Mavrodi A; Aletras V
Value Health Reg Issues; 2020 Sep; 22():36-43. PubMed ID: 32731168
[TBL] [Abstract][Full Text] [Related]
9. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
[TBL] [Abstract][Full Text] [Related]
10. Estimation of the value of curative therapies in oncology: a willingness-to-pay study in China.
Huang L; Peng X; Sun L; Zhang D
Cost Eff Resour Alloc; 2023 Jun; 21(1):37. PubMed ID: 37277820
[TBL] [Abstract][Full Text] [Related]
11. Willingness to Pay for a Quality-Adjusted Life Year among Gastrointestinal Cancer Patients at a Tertiary Hospital of Vietnam, 2022.
Tran BT; Tran TT; La NQ; Nguyen TTP; Nguyen MH; Huynh TMC; Vu HP
Asian Pac J Cancer Prev; 2024 May; 25(5):1725-1735. PubMed ID: 38809645
[TBL] [Abstract][Full Text] [Related]
12. An exploratory study to estimate cost-effectiveness threshold value for life saving treatments in western Iran.
Moradi N; Woldemichael A; Malekian P; Rotvandi DM; Rezaei S
Cost Eff Resour Alloc; 2020; 18():47. PubMed ID: 33110399
[TBL] [Abstract][Full Text] [Related]
13. Willingness to pay for a quality-adjusted life-year: the individual perspective.
Bobinac A; Van Exel NJ; Rutten FF; Brouwer WB
Value Health; 2010 Dec; 13(8):1046-55. PubMed ID: 20825620
[TBL] [Abstract][Full Text] [Related]
14. Estimating the cost-effectiveness threshold of advanced non-small cell lung cancer in China using mean opportunity cost and contingent valuation method.
Peng Q; Yin Y; Liang M; Zhao M; Shao T; Tang Y; Mei Z; Li H; Tang W
Cost Eff Resour Alloc; 2023 Nov; 21(1):80. PubMed ID: 37915053
[TBL] [Abstract][Full Text] [Related]
15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
16. Willingness to Pay for One Additional Quality Adjusted Life Year: A Population Based Survey from China.
Ye Z; Abduhilil R; Huang J; Sun L
Appl Health Econ Health Policy; 2022 Nov; 20(6):893-904. PubMed ID: 35934772
[TBL] [Abstract][Full Text] [Related]
17. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
18. Willingness to pay for one quality-adjusted life year in Iran.
Moradi N; Rashidian A; Nosratnejad S; Olyaeemanesh A; Zanganeh M; Zarei L
Cost Eff Resour Alloc; 2019; 17():4. PubMed ID: 30867654
[TBL] [Abstract][Full Text] [Related]
19. Willingness to pay for a quality-adjusted life year: a systematic review with meta-regression.
Kouakou CRC; Poder TG
Eur J Health Econ; 2022 Mar; 23(2):277-299. PubMed ID: 34417905
[TBL] [Abstract][Full Text] [Related]
20. Willingness to pay per quality-adjusted life year in a study of knee osteoarthritis.
Byrne MM; O'malley K; Suarez-Almazor ME
Med Decis Making; 2005; 25(6):655-66. PubMed ID: 16282216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
